Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab in Advanced Uveal Melanoma
NCT01034787Phase 2Completed
- Sponsor
- American Health Staffing Group
- Start
- Aug 2009
- Primary completion
- Aug 2017
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab in Uveal melanoma (UM), sponsored by American Health Staffing Group. Started Aug 2009; status: completed.
02
Drugs
tremelimumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT01034787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01034787.